Biofilms comprise structured communities of microorganisms in a self-produced extracellular matrix, usually attached to an organic or abiotic surface.
For many bacteria, including a substantial proportion of those that cause human disease, the biofilm represents the usual mode of growth. Infections involving a substantial biofilm component (e.g. chronic wounds) are notoriously difficult to treat; not only does the physiological status of the bacteria inside the biofilm render them refractory to killing by extant anti bacterial drugs, but the extracellular matrix acts to physically shield the inhabitants from attack by the host’s immune system. One approach to address the current difficulties we face in treating bio-film infections is to discover new antibacterial agents that demonstrate substantial killing and or eradication of bacterial biofilms.